Virginia Tech® home

Virtual Seminar: Von Willebrand Factor Inhibition in Acute Ischemic Stroke: From Target to Trial

Insert your title here

Your Text Here
Shahid Nimjee, M.D., Ph.D.

Shahid Nimjee, M.D., Ph.D.

Associate Professor of Neurological Surgery
Co-Director, Stroke Center
Wexner Medical Center
The Ohio State University

Virtual Timothy A. Johnson Medical Scholar Lecture: Von Willebrand Factor Inhibition in Acute Ischemic Stroke: From Target to Trial

Sept. 23, 2022

1 to 2 p.m.

View Speaker Profile
Download Flyer

About this Seminar

Acute ischemic stroke (AIS) is the leading cause of combined morbidity and mortality worldwide. Recombinant tissue plasminogen activator (rtPA) is the only approved pharmacological treatment for AIS but is limited to treating patients within 4.5 hours of stroke onset because of the risk of intracranial hemorrhage. Moreover, it is ineffective in treating large vessel occlusion (LVO) stroke. Endovascular mechanical thrombectomy (MT) effectively recanalizes LVO stroke but it is  limited to highly-specialized hospitals, leaving the vast majority without timely acute treatment. Dr. Nimjee hypothesizes that targeted von Willebrand Factor (VWF) inhibition by BB-031 will recanalize arterial thrombosis in a canine model of LVO stroke. Utilizing a canine embolic middle cerebral artery occlusion (eMCAO) model of LVO stroke, his lab assessed BB-031 administration at 0.5mg/kg 6 hours after stroke induction on platelet activity by PFA-100, vessel recanalization by digital subtraction angiography, infarct volume and intracranial hemorrhage by MRI. BB-031 administration after 6 hours of LVO stroke resulted complete inhibition of platelet activity. Moreover, it recanalized MCAO to >TICI 2A in 62.5% and >TICI 2B in 50% of canines (n=8). Negative control group demonstrated no revascularization (n=7). Recanalization resulted in reduced infarct volume compared to negative control (p<0.05). BB-031 administration induced no intracranial hemorrhage. VWF inhibition by BB-031 completely inhibited platelet activity, and effectively recanalizes LVO when administered 6 hours after stroke onset. Recanalization resulted in reduced infarct volume, without any incidence of intracranial hemorrhage. Targeted therapy against VWF represents a robust yet safe approach to treat AIS.

Additional Details

This is a free event hosted by the Fralin Biomedical Research Institute and the Virginia Tech Carilion School of Medicine. The Timothy A. Johnson Medical Scholar Lecture Series hosts clinician scientists who are exploring frontiers of medicine. These lectures are principally intended for Virginia Tech Carilion School of Medicine students and Virginia Tech students in the Translational Biology, Medicine, and Health graduate program. Virginia Tech and Carilion Clinic faculty, staff, and students may also attend.

fbri logo

You May Also Be Interested In...

  • Home Item
    Inheriting Chromatin Domains in Mammals and the Mechanisms Involved
    Inheriting Chromatin Domains in Mammals and the Mechanisms Involved , home

    Sept. 5, 2025, 11:00 a.m. | Thelma Escobar, Ph.D., Assistant Professor, Department of Biochemistry, Institute for Stem Cell & Regenerative Medicine, University of Washington | Co-Sponsored by the Fralin Biomedical Research Institute and Cancer Research Center — D.C.

  • Home Item
    Flow Induced Endothelial Planar Polarity for Signaling Regulation
    Flow Induced Endothelial Planar Polarity for Signaling Regulation , home

    Sept. 19, 2025, 11:00 a.m. | Julia Mack, Ph.D., Assistant Adjunct Professor, David Geffen School of Medicine, Division of Cardiology, University of California Los Angeles | Co-Sponsored by the Fralin Biomedical Research Institute Center for Vascular and Heart Research

  • Home Item
    Maury Strauss Distinguished Public Lecture
    Maury Strauss Distinguished Public Lecture , home

    Sept. 18, 2025, 5:30 p.m. (Reception at 5 p.m.) | Robert Gourdie, Ph.D., FAHA, AIMBE, Heywood Fralin Professor and Director, Center for Vascular and Heart Research, Fralin Biomedical Research Institute; Professor, Department of Biomedical Engineering and Mechanics, Virginia Tech College of Engineering; Elected Member, National Academy of Inventors | Maury Strauss Distinguished Public Lecture

  • Home Item
    The Bitter Truth: Alcohol Use and Its Effects on Chemosensory Function
    The Bitter Truth: Alcohol Use and Its Effects on Chemosensory Function , home

    Oct. 3, 2025, 11:00 a.m. | Paule Valery Joseph, Ph.D., Lasker Clinical Research Scholar, NIH Distinguished Scholar; Acting Chief, Section of Sensory Science and Metabolism Unit, Co-Director of the National Smell and Taste Center, National Institute on Deafness and Other Communication Disorders; National Institute of Alcohol Abuse and Alcoholism, National Institutes of Health | Co-Sponsored by the Fralin Biomedical Research Institute Center for Health Behaviors Research and Addiction Recovery Research Center

  • Home Item
    Organization and Control of Hippocampal Networks
    Organization and Control of Hippocampal Networks , home

    Oct. 17, 2025, 11:00 a.m. | Ivan Soltesz, Ph.D., James R. Doty Professor of Neurosurgery and Neurosciences, Stanford University | Co-Sponsored by the Fralin Biomedical Research Institute Center for Neurobiology Research

  • Home Item
    Thinking the Right Thoughts
    Thinking the Right Thoughts , home

    Oct. 31, 2025, 11 a.m. | Nathaniel Daw, Ph.D., Professor, Computational and Theoretical Neuroscience, Department of Psychology, Princeton University | Co-Sponsored by the Fralin Biomedical Research Institute Center for Human Neuroscience Research